----

| (Mark One)                                                                                                               |
|--------------------------------------------------------------------------------------------------------------------------|
| [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934                         |
|                                                                                                                     |   |
|                                                                                                                     | For the quarterly period ended March 31, 2019 |
|                                                                                                                     |   |
| [   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
|                                                                                                                     |   |
|                                                                                                                     | For the transition period from __________ to __________ |
| 000-53089                                                                                      |
|------------------------------------------------------------------------------------------------|
| Commission File Number                                                                         |
|                                                                                           |
| Rafina Innovations Inc.                                                                        |
| (Exact name of registrant as specified in its charter)                                         |
|                                                                                           |   |
| Nevada                                                                                         | 30-0428006 |
| (State or other jurisdiction of incorporation or organization)                                 | (I.R.S. Employer Identification No.) |
|                                                                                           |   |
| Kintyre House, 209 Govan Road, Glasgow Scotland                                                | G51 1HJ |
| (Address of principal executive offices)                                                       | (Zip Code) |
|                                                                                           |
| +44 141 370 0321                                                                               |
| (Registrant's telephone number, including area code)                                      |
|                                                                                           |
|                                                                                           |
|  (Former name, former address and former fiscal year, if changed since last report)  |
|   | Yes |  [X] | No |  [   ] |
|--------|-----|-----------|----|----------------------------|
|   | Yes |  [X] | No |  [   ] |
|--------|-----|-----------|----|----------------------------|
|                                                                              |                             |
|-----------------------------------------------------------------------------------|----------------------------------|
| Large accelerated filer[  ]                                                  | Accelerated filer [  ]      |
| Non-accelerated filer[  ] (Do not check if a smaller reporting company) | Smaller reporting company [X]    |
|                                                                              | Emerging growth company [X] |
|   | Yes |  [  ] | No |  [X] |
|--------|-----|----------------------|----|-----------|
|   | Yes |  [   ] | No |  [   ] |
|--------|-----|----------------------------|----|----------------------------|
| 15,719,681 shares of common stock issued and outstanding as of May 20, 2019 |
|----------------------------------------------------------------------------------|

----

|    |                                                                                  | Page     |
|---------|---------------------------------------------------------------------------------------|----------|
|    | PART I – Financial Information                                                  |     |
|    |                                                                                  |     |
| Item 1  | Financial Statements                                                                  |  4  |
| Item 2  | Management's Discussion and Analysis of Financial Condition and Results of Operations |  5  |
| Item 3  | Quantitative and Qualitative Disclosures About Market Risk                            |  9  |
| Item 4  | Controls and Procedures                                                               |  9  |
|    |                                                                                  |     |
|    | PART II – Other Information                                                     |     |
|    |                                                                                  |     |
| Item 1  | Legal Proceedings                                                                     |  10 |
| Item 1A | Risk Factors                                                                          |  10 |
| Item 2  | Unregistered Sales of Equity Securities and Use of Proceeds                           |  10 |
| Item 3  | Defaults Upon Senior Securities                                                       |  11 |
| Item 4  | Mine Safety Disclosures                                                               |  11 |
| Item 5  | Other Information                                                                     |  11 |
| Item 6  | Exhibits                                                                              |  12 |
|    | SIGNATURES                                                                            |  12 |

----

----

|                                                                               | Page              |
|------------------------------------------------------------------------------------|-------------------|
| Condensed Consolidated Balance Sheets (Unaudited)                             |  F-1         |
| Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) |  F-2         |
| Condensed Consoldiated Statements of Stockholders Equity (Deficit)                 |  F-3         |
| Condensed Consolidated Statements of Cash Flows (Unaudited)                        |  F-4         |
| Notes to Condensed Consolidated Financial Statements (Unaudited)                   |  F-5 to F-24 |

----

|                                                                                                                                                    |   | March 31,2019 |        |   | December 31, 2018 |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------|---------------|-------------|--------|-------------------|--------|
|                                                                                                                                                    |   |          |        |   |              |   |
| ASSETS                                                                                                                                                  |   |          |        |   |              |   |
|                                                                                                                                                    |   |          |        |   |              |   |
| Current Assets:                                                                                                                                         |   |          |        |   |              |   |
| Cash and cash equivalents                                                                                                                               |   | $             | 17,258      |   |              |   | 18,827 |   |
| Accounts receivable                                                                                                                                     |   |          | 58,677      |   |              |   | 80,197 |   |
| Other receivables                                                                                                                                       |   |          | 79,929      |   |              |   | 80,419 |   |
| Inventory                                                                                                                                               |   |          | 4,248       |   |              |   | 4,149 |   |
| Prepaid expenses                                                                                                                                        |   |          | 47,703      |   |              |   | 46,785 |   |
|           Total Current Assets                                                                        |   |          | 207,815     |   |              |   | 230,377 |   |
|                                                                                                                                                    |   |          |        |   |              |   |   |   |
| Property, plant and equipment, net                                                                                                                      |   |          | 54,539      |   |              |   | 68,283 |   |
| Right of use assets                                                                                                                                     |   |          | 39,528      |   |              |   | - |   |
|                                                                                                                                                    |   |          |        |   |              |   |   |   |
| Total Assets                                                                                                                                            |   | $             | 301,882     |   |              |   | 298,660 |   |
|                                                                                                                                                    |   |          |        |   |              |   |   |   |
| LIABILITIES AND STOCKHOLDERS' DEFICIT                                                                                                                   |   |          |        |   |              |   |   |   |
|                                                                                                                                                    |   |          |        |   |              |   |   |   |
| Current Liabilities:                                                                                                                                    |   |          |        |   |              |   |   |   |
| Accounts payable, advances and accrued expenses                                                                                                         |   | $             | 617,080     |   |              |   | 571,531 |   |
| Accounts payable and accrued expenses, related party                                                                                                    |   |          | 52,210      |   |              |   | 47,382 |   |
| Income tax penalties payable                                                                                                                            |   |          | 80,000      |   |              |   | 80,000 |   |
| Advances from a related party                                                                                                                           |   |          | 15,147      |   |              |   | 14,881 |   |
| Notes payable, third parties                                                                                                                            |   |          | 78,982      |   |              |   | 79,091 |   |
| Lease liability                                                                                                                                         |   |          | 46,700      |   |              |   | - |   |
|           Total Current Liabilities                                                                   |   |          | 890,119     |   |              |   | 792,885 |   |
| Total Liabilities                                                                                                                                       |   |          | 890,119     |   |              |   | 792,885 |   |
|                                                                                                                                                    |   |          |        |   |              |   |   |   |
| Commitments and Contingencies                                                                                                                           |   |          | -           |   |              |   | - |   |
|                                                                                                                                                    |   |          |        |   |              |   |   |   |
| Stockholders' Equity (Deficit):                                                                                                                         |   |          |        |   |              |   |   |   |
| Preferred stock, par value $0.0001, 5,000,000 shares authorized; none issued and outstanding as of March 31, 2019 and December 31, 2018            |   |          | -           |   |              |   | - |   |
| Common stock, par value $0.0001, 35,000,000 shares authorized; 15,719,681 shares issued and outstanding as of March 31, 2019 and December 31, 2018 |   |          | 1,572       |   |              |   | 1,572 |   |
| Additional paid-in capital                                                                                                                              |   |          | 40,676,120  |   |              |   | 40,146,912 |   |
| Accumulated deficit                                                                                                                                     |   |          | (41,208,048 | )      |              |   | (40,586,465 | ) |
| Accumulated other comprehensive income (loss)                                                                                                      |   |          | (57,881     | )      |              |   | (56,244 | ) |
| Stockholders' equity (deficit)                                                                                                                          |   |          | (588,237    | )      |              |   | (494,225 | ) |
| Total Liabilities and Stockholders' Equity (Deficit)                                                                                                    |   | $             | 301,882     |   |              |   | 298,660 |   |

----

|                                                                                      |   | For the Three Months ended |       |
|-------------------------------------------------------------------------------------------|--------|----------------------------|------------|
|                                                                                      |   | March 31,                  |       |
|                                                                                      |   | 2019                       |       |   | 2018 |   |
| Sales                                                                                     |   | $                          | 54,248     |   |   | $ | 131,780 |   |
| Cost of goods sold                                                                        |   |                       | 12,517     |   |   |   | (39,503 | ) |
|          Gross Profit                        |   |                       | 66,765     |   |   |   | 92,277 |   |
|                                                                                      |   |                       |       |   |   |   |   |   |
| Operating Expenses                                                                        |   |                       |       |   |   |   |   |   |
| Depreciation                                                                              |   |                       | 14,995     |   |   |   | 19,455 |   |
| General and administrative expenses                                                       |   |                       | 57,173     |   |   |   | 127,559 |   |
| Consultancy Fees                                                                          |   |                       | 537,208    |   |   |   | 537,225 |   |
| Professional fees                                                                         |   |                       | 17,652     |   |   |   | 19,436 |   |
| Research and development                                                                  |   |                       | 58,937     |   |   |   | 83,328 |   |
|           Total Operating Expenses      |   |                       | 685,965    |   |   |   | 787,003 |   |
|                                                                                      |   |                       |       |   |   |   |   |   |
| Income (Loss) from Operations                                                             |   |                       | (619,200   | ) |   |   | (694,726 | ) |
|                                                                                      |   |                       |       |   |   |   |   |   |
| Other Income (Expenses)                                                                   |   |                       |       |   |   |   |   |   |
| Gain (Loss) on foreign currency transaction                                               |   |                       | (678       | ) |   |   | 1,825 |   |
| Interest Expenses due to third party                                                      |   |                       | (1,705     | ) |   |   | (614 | ) |
|           Total Other Income (Expenses) |   |                       | (2,383     | ) |   |   | 1,211 | ) |
|                                                                                      |   |                       |       |   |   |   |   |   |
| Income (Loss) before Provision for Income Tax                                             |   |                       | (621,583   | ) |   |   | (693,515 | ) |
|                                                                                      |   |                       |       |   |   |   |   |   |
| Provision for Income Tax                                                                  |   |                       | -          |   |   |   | - |   |
|                                                                                      |   |                       |       |   |   |   |   |   |
| Net Income (Loss)                                                                         |   | $                          | (621,583   | ) |   | $ | (693,515 | ) |
|                                                                                      |   |                       |       |   |   |   |   |   |
| Basic and fully diluted loss per share                                                    |   | $                          | (0.04      | ) |   | $ | (0.06 | ) |
|                                                                                      |   |                       |       |   |   |   |   |   |
| Weighted average shares outstanding                                                       |   |                       | 15,719,681 |   |   |   | 12,302,432 |   |
|                                                                                      |   |                       |       |   |   |   |   |   |
| Comprehensive Income (Loss):                                                              |   |                       |       |   |   |   |   |   |
| Net loss                                                                                  |   | $                          | (621,583   | ) |   | $ | (693,515 | ) |
| Effect of foreign currency translation                                                    |   |                       | (1,637     | ) |   |   | (30,881 | ) |
| Comprehensive Loss                                                                        |   | $                          | (623,220   | ) |   | $ | (724,396 | ) |

----

| Rafina Innovations Inc.(Formerly HCi Viocare)                                  |
|--------------------------------------------------------------------------------|
| CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)(Unaudited) |
|                                                               |   | Common stock |       |   | AdditionalPaid-in |   |   | Accumulatedothercomprehensive |   |   | Retained      |   |   | Total   |    |
|--------------------------------------------------------------------|--------|--------------|------------|--------|-------------------|--------|--------|-------------------------------|--------|--------|---------------|--------|--------|---------|---------|
|                                                               |   | Shares       |       |   | Amount            |   |   | Capital                       |   |   | income (loss) |   |   | deficit |    |   | Deficit |   |
| Balances, December 31, 2017                                   |   |         | 11,919,306 |   |              | $      | 1,192  |                          |   | $      | 33,841,702    |   |   | $       | (17,340 | ) |   | $ | (34,736,633 | ) |   | $ | (911,079 | ) |
|                                                               |   |         |       |   |              |   |   |                          |   |   |          |   |   |    |    |   |   |   |   |   |   |   |   |   |
| Proceeds from issuance of common stock for private placements |   |         | 607,410    |   |              |   | 61     |                          |   |   | 359,319       |   |   |    | -       |   |   |   | - |   |   |   | 359,380 |   |
| Share issuances for stock awards                                   |   |         | 275,000    |   |              |   | 28     |                          |   |   | 272,472       |   |   |    | -       |   |   |   | - |   |   |   | 272,500 |   |
| Stock options                                                      |   |         | -          |   |              |   | -      |                          |   |   | 184,643       |   |   |    | -       |   |   |   | - |   |   |   | 184,643 |   |
| Net income (loss)                                                  |   |         | -          |   |              |   | -      |                          |   |   | -             |   |   |    | -       |   |   |   | (693,515 | ) |   |   | (693,515 | ) |
| Foreign currency translation adjustments                           |   |         | -          |   |              |   | -      |                          |   |   | -             |   |   |    | (30,881 | ) |   |   | - |   |   |   | (30,881 | ) |
| Balances, March 31, 2018                                           |   |         | 12,801,716 |   |              | $      | 1,281  |                          |   | $      | 34,658,136    |   |   | $       | (48,221 | ) |   | $ | (35,430,148 | ) |   | $ | (818,952 | ) |
|                                                               |   |         |       |   |              |   |   |                          |   |   |          |   |   |    |    |   |   |   |   |   |   |   |   |   |
| Balances, December 31, 2018                                   |   |         | 15,719,681 |   |              | $      | 1,572  |                          |   | $      | 40,146,912    |   |   | $       | (56,244 | ) |   | $ | (40,586,465 | ) |   | $ | (494,225 | ) |
| Stock options                                                      |   |         | -          |   |              |   | -      |                          |   |   | 529,208       |   |   |    | -       |   |   |   | - |   |   |   | 529,208 |   |
| Net income (loss)                                                  |   |         | -          |   |              |   | -      |                          |   |   | -             |   |   |    | -       |   |   |   | (621,583 | ) |   |   | (621,583 | ) |
| Foreign currency translation adjustments                           |   |         | -          |   |              |   | -      |                          |   |   | -             |   |   |    | (1,637  | ) |   |   | - |   |   |   | (1,637 | ) |
| Balances, March 31, 2019                                           |   |         | 15,719,681 |   |              | $      | 1,572  |                          |   | $      | 40,676,120    |   |   | $       | (57,881 | ) |   | $ | (41,208,048 | ) |   | $ | (588,237 | ) |

----

|                                                                                                 |   | For the Three Months Ended |     |
|------------------------------------------------------------------------------------------------------|--------|----------------------------|----------|
|                                                                                                 |   | March 31,                  |     |
|                                                                                                 |   | 2019                       |     |   | 2018 |   |
|                                                                                                 |   |                       |     |   |   |   |
| Operating Activities                                                                                 |   |                       |     |   |   |   |
| Net loss                                                                                             |   | $                          | (621,583 | ) |   | $ | (693,515 | ) |
| Adjustments to reconcile net loss to net cash used by operating activities:                          |   |                       |     |   |   |   |   |   |
| Stock option expense                                                                                 |   |                       | 529,208  |   |   |   | 184,643 |   |
| Shares issued for stock award                                                                        |   |                       | -        |   |   |   | 272,500 |   |
| Depreciation                                                                                         |   |                       | 14,995   |   |   |   | 19,455 |   |
| Amortization of right of use asset                                                                   |   |                       | 639      |   |   |   | - |   |
| Changes in operating assets and liabilities:                                                         |   |                       |     |   |   |   |   |   |
| Decrease (Increase) in accounts receivable                                                           |   |                       | 23,576   |   |   |   | (34,143 | ) |
| Decrease (Increase) in prepaid expense                                                               |   |                       | -        |   |   |   | (3,879 | ) |
| Decrease (Increase) in other receivable                                                              |   |                       | -        |   |   |   | (881 | ) |
| Increase (Decrease) in accounts payable and accrued expenses                                         |   |                       | 39,738   |   |   |   | (53,412 | ) |
| Increase (Decrease) in accounts payable and accrued expenses, related party                          |   |                       | 6,456    |   |   |   | (102,149 | ) |
| Change in right of use liability                                                                     |   |                       | 6,456    |   |   |   | - |   |
| Net cash used by operating activities                                                                |   |                       | (515     | ) |   |   | (411,381 | ) |
|                                                                                                 |   |                       |     |   |   |   |   |   |
| Investing Activities                                                                                 |   |                       |     |   |   |   |   |   |
| Net cash (used) by investing activities                                                              |   |                       | -        |   |   |   | - |   |
|                                                                                                 |   |                       |     |   |   |   |   |   |
| Financing Activities                                                                                 |   |                       |     |   |   |   |   |   |
| Advances and Loans from related parties                                                              |   |                       | 567      |   |   |   | 64,603 |   |
| Repayments, advances and loans from related party                                                    |   |                       | -        |   |   |   | (122,427 | ) |
| Proceeds from private placement                                                                      |   |                       | -        |   |   |   | 359,381 |   |
| Net cash provided by financing activities                                                            |   |                       | 567      |   |   |   | 301,557 |   |
|                                                                                                 |   |                       |     |   |   |   |   |   |
| Increase (decrease) in cash                                                                          |   |                       | 52       |   |   |   | (109,824 | ) |
|                                                                                                 |   |                       |     |   |   |   |   |   |
| Cash at beginning of period                                                                          |   |                       | 18,827   |   |   |   | 352,498 |   |
| Effects of exchange rates on cash                                                                    |   |                       | (1,621   | ) |   |   | (8,294 | ) |
| Cash at end of period                                                                                |   | $                          | 17,258   |   |   | $ | 234,380 |   |
|                                                                                                 |   |                       |     |   |   |   |   |   |
| Supplemental Disclosures of Cash Flow Information:                                                   |   |                       |     |   |   |   |   |   |
| Cash paid during the year for:                                                                       |   |                       |     |   |   |   |   |   |
| Interest                                                                                             |   | $                          | -        |   |   | $ | - |   |
| Income taxes                                                                                         |   | $                          | -        |   |   | $ | - |   |
|                                                                                                 |   |                       |     |   |   |   |   |   |
| Supplemental Non-Cash Activities                                                                     |   |                       |     |   |   |   |   |   |
| Reclassification of related party accounts payable and advances to convertible debt, related parties |   | $                          | -        |   |   | $ | 721,564 |   |
|                                                                                                 |   |                       |     |   |   |   |   |   |

----

----

----

----

| i) | assets and liabilities are translated at the closing rate at the date of the balance sheet, or |
|----|------------------------------------------------------------------------------------------------|
| ii) | income and expenses are translated at average exchange rates for three months ended March 31, or |
|-----|--------------------------------------------------------------------------------------------------|
| iii) | all resulting exchange differences are recognized as other comprehensive income, a separate component of equity. |
|------|------------------------------------------------------------------------------------------------------------------|

----

----

----

|                                                                             |   | March 31, 2019 |      |   | December 31, 2018 |   |
|----------------------------------------------------------------------------------|--------|----------------|-----------|--------|-------------------|--------|
| Common stock issuable upon conversion of 25,000 Series A Preferred Stock Options |   |           | 500,000   |   |              |   | 500,000 |   |
| Common stock issuable upon exercise of stock options                             |   |           | 7,500,000 |   |              |   | 7,500,000 |   |
| Total                                                                            |   |           | 8,000,000 |   |              |   | 8,000,000 |   |

----

|                                                      |   | March 31, 2019 |   |   | December31, 2018 |   |
|-----------------------------------------------------------|--------|----------------|--------|--------|------------------|--------|
| Office lease, including security deposits                 |   | $              | 38,276 |   |             | $      | 37,403 |   |
| Travel advances and other expenses                        |   |           | 9,427  |   |             |   | 9,382 |   |
|       Total prepaid expense |   | $              | 47,703 |   |             | $      | 46,785 |   |
|                                          |   | March 31,2019 |     |   | December 31, 2018 |   |
|-----------------------------------------------|--------|---------------|----------|--------|-------------------|--------|
| Cost                                          |   |          |     |   |              |   |
| Leasehold improvements                        |   | $             | 195,678  |   |              | $      | 193,109 |   |
| Furniture and fixture                         |   |          | 31,340   |   |              |   | 31,072 |   |
| Computers and equipment                       |   |          | 32,637   |   |              |   | 32,426 |   |
| Vehicle                                       |   |          | 56,100   |   |              |   | 57,230 |   |
| Machine and plant                             |   |          | 8,897    |   |              |   | 8,690 |   |
| Lab equipment                                 |   |          | 32,978   |   |              |   | 32,209 |   |
| Subtotal                                      |   |          | 357,630  |   |              |   | 354,736 |   |
| Less: accumulated depreciation and impairment |   |          | (303,091 | )      |              |   | (286,453 | ) |
| Total                                         |   | $             | 54,539   |   |              | $      | 68,283 |   |

----

|                        |   | March 31, 2019 |   |
|-----------------------------|--------|----------------|--------|
| Assets                      |   |           |   |
| Operating lease assets      |   | $              | 39,528 |   |
|                        |   |           |   |   |
| Liabilities                 |   |           |   |   |
| Operating lease liabilities |   | $              | 46,700 |   |
|                                                     |   | Three Months Ended March 31, 2019 |   |
|----------------------------------------------------------|--------|-----------------------------------|--------|
|                                                     |   |                              |   |
| Cash used in operating activities:                       |   |                              |   |
| Operating leases                                         |   | $                                 | 12,887 |   |
| ROU assets recognized in exchange for lease obligations: |   |                              |   |   |
| Operating leases                                         |   | $                                 | 38,320 |   |
|                 |   | March 31, 2019 |   |
|----------------------|--------|----------------|--------|
| Remaining lease term |   | 11 months      |   |
| Discount rate        |   |           | 4.75%  |   |
|                                                   |   | OperatingLeases |   |
|--------------------------------------------------------|--------|-----------------|--------|
|                                                   |   |            |   |
| 2019 (excluding the three months ended March 31, 2019) |   | $               | 39,123 |   |
| 2020                                                   |   |            | 8,693  |   |
| Total lease payments                                   |   |            | 47,816 |   |
| Less: amount of lease payments representing interest   |   |            | (1,116 | ) |
| Present value of future minimum lease payments         |   | $               | 46,700 |   |

----

| (1) | Consulting Agreement with Dr. Christos Kapatos |
|-----|------------------------------------------------|
| (2) | Consulting Agreement with Ms. Paraskevi Pilarinou |
|-----|---------------------------------------------------|

----

|  (3) | Consulting Agreement with Charalampos Sgardelis |
|-----------|-------------------------------------------------|
| (4) | Advisory Agreement with Ravi Vaidyanathan |
|-----|-------------------------------------------|
| (5) | Addendum to Service Agreement with Nikolaos Gemelos |
|-----|-----------------------------------------------------|
| (6) | Service Agreement with Georgios Dritsoulas |
|-----|-------------------------------------------------|

----

| (a) | Services provided from related parties: |
|-----|-----------------------------------------|
|                                                      |   | Three Months endedMarch 31, |    |
|-----------------------------------------------------------|--------|-----------------------------|---------|
|                                                      |   | 2019                        |    |   | 2018 |   |
| Consulting fees paid to former CEO and President (i) |   | $                           | -       |   |   | $ | 38,867 |   |
| Consulting fees paid to former Director (ii)         |   |                        | -       |   |   |   | 15,361 |   |
| Professional fees paid to former Director (iii)      |   |                        | -       |   |   |   | 3,687 |   |
| Consulting fees paid to former VP (iv)                    |   |                        | -       |   |   |   | 12,903 |   |
| Consulting fees paid to Director and CFO (v)              |   |                        | 6,814   |   |   |   | - |   |
| Stock options granted to Directors and Officers           |   |                        | 529,208 |   |   |   | - |   |
| Stock options granted to former Directors and Officers    |   |                        | -       |   |   |   | 184,643 |   |
|                                                      |   | $                           | 536,022 |   |   | $ | 255,461 |   |
| (i) | On September 10, 2013 Mr. Leontaritis was appointed President. On January 15, 2014, the Board of Directors of the Company approved the execution of a consulting agreement between the Company and Sotirios Leontaritis ("Leontaritis"), whereby Leontaritis shall provide services to the Company as the Company's President and Chief Executive Officer in regard to the Company's management and operations for the period from January 1, 2014 to December 31, 2016.   Under the terms of the agreement, the Company agreed to pay to Leontaritis US$60,000 per annum payable in monthly payments of US$5,000 a month for the term of the contract. On January 1, 2017, the Company approved a three-year extension to the consulting agreement. Mr. Leontaritis will continue to serve for a term of three years, effective as of January 1, 2017, and ending on December 31, 2019; the Company shall pay to Leontaritis US$120,000 per annum payable in monthly payments of US$10,000 a month for the term of the contract.  In January 2018, the Company agreed to revise the currency of Mr. Leontaritis salary, and his compensation changed from US$10,000 per month to EUR10,000 (USD$11,650) per month.  Further, Mr. Leontaritis is entitled to acquire at his discretion 150,000 shares of the common stock at a price of $6 per share for a term of five (5) years.  The Company recognized stock-based compensation expense allocated to consulting fees of $367,629 and $245,086 during the years ended December 31, 2018 and 2017. On October 3, 2018 Mr. Leontaritis resigned all positions with the Company and his contract was terminated.   Further concurrent with his resignation, and with an effective date of September 30, 2018, Mr. Leontaritis and the Company entered into an agreement whereunder Mr. Leontaritis settled certain amounts payable to the Company totaling $134,402. The Company recorded a loss on debt settlement of $514 in respect to the transaction. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (ii) | On September 30, 2013, the Board of Directors of the Company appointed Dr. Christos Kapatos as a director of the Company. On April 16, 2014, the Company entered into a consulting contract with Dr. Kapatos where under his compensation shall be USD$46,430 (€40,000) per year payable in equal monthly installments beginning on May 1, 2014. On May 1, 2015, the Company approved a one-year extension of the consulting agreement, and on August 2, 2016 the Company approved a further one-year extension so that the agreement will expire April 16, 2017. During fiscal 2017 and fiscal 2016 Dr. Kapatos invoiced the Company Euros €40,000 for services rendered in each fiscal year respectively. On December 12, 2017, the Company approved the issuance of 925,000 common shares to Dr. Christos Kapatos, CTO and Director of the Company, as consideration for the transfer of certain complementary technological developments and work in progress, in the form of a stock award which vested as of the date of grant.  The 925,000 shares have been valued at $925,000, or $1.00 per share, the fair market value on grant date, which amount has been expensed as research and development expenses. Concurrently, the Company approved a six-year extension to the consulting agreement with Dr. Kapatos. The revision to the Agreement ("Addendum No. 3") has a term of six years, being effective as of April 16, 2017, and ending on April 15, 2023, renewable for such further term as may be mutually agreed between the parties. As per Addendum No. 3 Mr. Kapatos shall receive annual compensation of EUR50,000 (US$58,250) and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Dr Kapatos shall also be entitled to acquire at his discretion 1,250,000 shares of the common stock at a price of US$1.00 for a term of six years. On May 23, 2018 the Company approved an amendment to the term of the scientific advisory agreement with Dr. Christos Kapatos, board member CTO and member of the Scientific Advisory Board, originally entered into on April 15, 2014 in order to extend the term to April 15, 2019. The Company recognized stock-based compensation expense allocated to consulting fees of $135,900 and $15,100 during the years ended December 31, 2018. Effective October 3, 2018, Dr Christos Kapatos resigned from his position as Director of the Company.  On November 21, 2018, Dr. Christos Kapatos resigned his position as Chief Technology Officer and as a consultant due to the Company's breach of Sections 3.1 and 3.2 of that certain Consulting Agreement originally entered into April 16, 2014 (as amended from time to time, including, without limitation, Addendum 1, Addendum 2 and Addendum 3, collectively, the "Consulting Agreement").  The Company declined to cure the noticed breach(es) in the ten (10) day period as allotted from notice date and subsequently accepted the resignation of Dr. Kapatos effective November 21, 2018.  Further, on December 4, 2018 the Company notified Dr. Kapatos of the termination of that certain Acquisition agreement between Dr. Kapatos and HCI VIOCARE TECHNOLOGIES LIMITED, the Company's wholly owned subsidiary, dated April 16, 2014, as amended May 8, 2015 (collectively the "Acquisition Agreement").  |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (iii) | On September 10, 2013, the Board of Directors of the Company elected Nikolaos Kardaras as Secretary and a director of the Company. During each of fiscal 2017 and fiscal 2016, Mr. Kardaras invoiced the Company EUR12,000 for services rendered in his capacity as a director which amount totaled US$13,500 and $13,300 respectively. During 2018, Mr. Kardaras invoiced the Company EUR9,000 (USD$10,747) On March 3, 2017, the Company approved the issuance of 50,000 common shares for the services provided by Mr. Nikolaos Kardaras in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $172,000, the fair market value of $3.44 per share on issue date, which amount has been expensed as stock-based compensation.  On October 3, 2018 Mr. Kardaras resigned as secretary and director of the Company.  He remains the Company's in house legal advisor. |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a) | Services provided from related parties (cont'd) |
|-----|-------------------------------------------------|
|  (iv) | On September 1, 2015, the Board of Directors of the Company approved a consulting agreement with Sergios Katsaros and appointed Mr. Katsaros Vice President. Under the terms of the consulting agreement, Mr. Katsaros will work directly with the Company's President and CEO in order to create and implement the Company's strategic plan and assist in securing additional financing to meet the needs of the Company's business plan and corporate objectives.  The initial term of the contract is six months and Mr. Katsaros will receive compensation of USD$2,330 (€2,000) per month. On March 1, 2016, the Company approved a one-year extension to the consulting agreement and the Company approved the grant of a stock award of 15,000 common shares as compensation for the services provided by Vice President, Sergios Katsaros.  The award vests in three equal instalments of 5,000 shares as of the date of grant, the six-month anniversary of the date of grant and the 12-month anniversary of date of grant. During fiscal 2016 a total of $169,000 in respect of 10,000 vested shares was recorded as stock-based compensation. On March 1, 2017, the final installment of 5,000 shares were issued in accordance with the terms of the award valued at $17,200, the fair market value on grant date, which amount has been expensed as stock-based compensation in 2017. On March 17, 2017, the Company approved the issuance of a further 50,000 common shares for the services provided by Mr. Katsaros, in the form of a stock award which vested as of the date of grant. 50,000 shares have been valued at $170,000, the fair market value of $3.40 per share on grant date, which amount has been expensed as stock-based compensation. On December 12, 2017 the Company approved a three-year extension to the consulting agreement between the Company and Mr. Katsaros effective as of January 2, 2018.  The revision to the Agreement has a term of three years, being effective as of January 2, 2018, and ending on January 1, 2021, renewable for such further term as may be mutually agreed between the parties. Mr. Katsaros shall be remunerated with a monthly stipend of EUR3,500 (US$4,006), and shall be entitled to a 100% bonus of the total annual compensation for every profitable year of the Company. Mr. Katsaros shall also be entitled to acquire at his discretion 500,000 shares of the common stock at a price of US$1.00 for a term of five years commencing January 2, 2018. The Company recognized stock-based compensation expense allocated to consulting fees of $50,400 during year ended December 31, 2018. On November 17, 2018, the Company's management terminated a consulting contract with Mr. Sergios Katsaros which took effect as of December 22, 2018. |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (v) | On October 3, 2018, the Board of Directors of the Company appointed Miss Paraskevi Pylarinou ("Pylarinou") as a member of the Board of Directors, Secretary and CFO of the Company. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (vi) | On October 3, 2018 the Board of Directors appointed Mr. Constantinos Zertalis as a member of the Board of Directors and the President of the Company. On October 19, 2018 the Company's Board of Directors appointed Mr. Constantinos Zertalis, CEO, President and Director as Chairman of the Board of Directors. During the year ended December 31, 2018, Mr. Zertalis advanced EUR13,000 (USD$14,586) to the Company. During the three months ended March 31, 2019, Mr. Zertalis advanced further EUR500 (USD$561) to the Company. |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b) | Accounts payable and accrued liabilities from related parties: |
|-----|---------------------------------------------------------------------|
|                               |   | March 31, |   |   | December 31, |   |
|------------------------------------|--------|-----------|--------|--------|--------------|--------|
|                               |   | 2019      |   |   | 2018         |   |
| Former Director (ii)          |   |      | 14,560 |   |         |   | 14,853 |   |
| Consulting fees for former VP (iv) |   |      | 19,594 |   |         |   | 19,989 |   |
| Former Director (iii)         |   |      | 2,244  |   |         |   | 2,289 |   |
| Director and CFO (v)          |   |      | 12,892 |   |         |   | 8,573 |   |
| CEO and President                  |   |      | 2,920  |   |         |   | 1,678 |   |
|                               |   | $         | 52,210 |   |         | $      | 47,382 |   |
| (c) | Advances / other receivable from related parties: |
|-----|---------------------------------------------------|
|  Advances from related parties: |   | March 31, |   |   | December 31, |   |
|--------------------------------------|--------|-----------|--------|--------|--------------|--------|
|                                 |   | 2019      |   |   | 2018         |   |
| CEO and President                    |   |      | 15,147 |   |         |   | 14,881 |   |
|                                 |   | $         | 15,147 |   |         | $      | 14,881 |   |
| (d) | Convertible Debt, related parties: |
|-----|-----------------------------------------|

----

----

|                                  |   | March 31, 2019          |   |   | December 31, 2018                |   |
|---------------------------------------|--------|-------------------------|--------|--------|----------------------------------|--------|
|                                  |   | Series APreferred stock |   |   | Weighted Average Exercise Price$ |   |   | Series APreferred stock |   |   | Weighted Average Exercise Price$ |   |
| Outstanding at beginning of the year  |   |                    | 25,000 |   |                             |   | 0.04 |   |   |   | 25,000 |   |   |   | 0.04 |   |
|    Granted             |   |                    | -      |   |                             |   | - |   |   |   | - |   |   |   | - |   |
|    Exercised           |   |                    | -      |   |                             |   | - |   |   |   | - |   |   |   | - |   |
|    Expired or canceled |   |                    | -      |   |                             |   | - |   |   |   | - |   |   |   | - |   |
| Outstanding at the period             |   |                    | 25,000 |   |                             |   | 0.04 |   |   |   | 25,000 |   |   |   | 0.04 |   |

----

|                                      |   | March 31, 2019 |      |   | December 31, 2018                |   |
|-------------------------------------------|--------|----------------|-----------|--------|----------------------------------|--------|
|                                      |   | Commonstock    |      |   | Weighted Average Exercise Price$ |   |   | Commonstock |   |   | Weighted Average Exercise Price$ |   |
| Outstanding at beginning of the year      |   |           | 7,500,000 |   |                             |   | 0.70 |   |   |   | 1,400,000 |   |   |   | 1.54 |   |
|    Granted                 |   |           | -         |   |                             |   | - |   |   |   | 8,000,000 |   |   |   | 0.72 |   |
|    Exercised               |   |           | -         |   |                             |   | - |   |   |   | - |   |   |   | - |   |
|    Expired or canceled     |   |           | -         |   |                             |   | - |   |   |   | (1,900,000 | ) |   |   | 1.39 |   |
| Outstanding at the end of period          |   |           | 7,500,000 |   |                             |   | 0.70 |   |   |   | 7,500,000 |   |   |   | 0.70 |   |
| Exercisable (vested) at the end of period |   |           | 1,500,000 |   |                             |   | 0.70 |   |   |   | 1,500,000 |   |   |   | 0.70 |   |
|                             | Options GrantedSeptember 30, 2014 |   |
|----------------------------------|-----------------------------------|--------|
| Fair value of options granted    | 1.40 ~ 2.00                       |   |
| Assumptions used:                |                              |   |
| Expected life (years) (a)   |                              |   | 1.00 |   |
| Risk free interest rate (b) |                              |   | 0.11% |   |
| Volatility (c)              | 117.09 ~ 119.83 %                 |   |
| Dividend yield (d)          |                              |   | 0.00 |   |

----

|                             | Option Grant dates |
|----------------------------------|--------------------|
| Fair value of options granted    | 0.038 ~ 0.925      |
| Assumptions used:                |               |
| Expected life (years) (a)   | 5 ~ 6              |
| Risk free interest rate (b) | 1.93% ~ 3.05%      |
| Volatility (c)              | 175.40% ~ 254.86%  |
| Dividend yield (d)          |  0.00         |
|                        |   | Clinics(UK) |   |   | Technology(UK) |   |    | All Other(Greece) |   |   | Total    |   |
|----------------------------------|--------|-------------|--------|--------|----------------|--------|---------|-------------------|--------|--------|----------|--------|
|                             |   |        |   |   |           |   |    |              |   |   |     |   |
| Revenue                          |   | $           | 54,248 |   |           | $      | -       |              |   | $      | -        |   |   | $ | 54,248 |   |
| Depreciation & amortization  |   | $           | 1,511  |   |           | $      | 10,531  |              |   | $      | 2,953    |   |   | $ | 14,995 |   |
| Net (Loss) from operations       |   | $           | 26,859 |   |           | $      | (73,524 | )                 |   | $      | (574,918 | )      |   | $ | (621,583 | ) |
| Interest expenses                |   | $           | (498   | )      |           | $      | (639    | )                 |   | $      | (568     | )      |   | $ | (1,705 | ) |
| Income tax expenses              |   |        | -      |   |           |   | -       |              |   |   | -        |   |   |   | - |   |
| Assets                           |   | $           | 70,868 |   |           | $      | 141,981 |              |   | $      | 89,033   |   |   | $ | 310,882 |   |
| Expenditure on long-lived assets |   | $           |   |   |           | $      |    |              |   | $      | -        |   |   | $ | - |   |

----

|                        |   | Clinics(UK) |    |   | Technology(UK) |   |    | All Other(Greece) |   |   | Total    |   |
|----------------------------------|--------|-------------|---------|--------|----------------|--------|---------|-------------------|--------|--------|----------|--------|
|                             |   |        |    |   |           |   |    |              |   |   |     |   |
| Revenue                          |   | $           | 126,890 |   |           | $      | 4,890   |              |   | $      | -        |   |   | $ | 131,780 |   |
| Depreciation & amortization  |   | $           | 2,357   |   |           | $      | 11,247  |              |   | $      | 5,851    |   |   | $ | 19,455 |   |
| Net (Loss) from operations       |   | $           | 20,469  |   |           | $      | (76,551 | )                 |   | $      | (637,433 | )      |   | $ | (693,515 | ) |
| Interest expenses                |   | $           | -       |   |           | $      | -       |              |   | $      | (614     | )      |   | $ | (614 | ) |
| Assets                           |   | $           | 277,638 |   |           | $      | 146,554 |              |   | $      | 140,906  |   |   | $ | 565,098 |   |
| Expenditure on long-lived assets |   | $           | -       |   |           | $      | -       |              |   | $      | -        |   |   | $ | - |   |

----

----

| •   | Filing of 3 patents in the UK: pressure sensor system; pressure & shear; pressure & positioning (Dec 2014) (all of which patents were abandoned upon the filing of a new International (PCT) patent application in December 2015 which covers over 140 countries around the world, and includes further advances made to the sensor systems, and a wider range of applications in products that touch people's everyday lives;Filing of 4 national patents for the Flexisense technology, following the progression of the PCT patent:Chinese Patent ApplicationUnited States Patent ApplicationCanadian Patent ApplicationEuropean Patent Application  |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •   | 2 further patents drafted and pending filing during fiscal 2019, with a further 4 patent applications currently in draft form;                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| •   | In excess of 12 prototypes: including 4 different types of pressure & shear insoles and diabetic walkers; smart cushion, smart mattress, biPAP machine and Flexicuff for deep vein thrombosis, with several of these prototypes in the commercialization stage;  |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| •   | 1 proof of concept device: robotic surgical assistive device;                                                                                                                                                                                                                  |
| •   | High level diagrams or complex documentation and software for other innovations in the portfolio.  |
|---------------------|---------------------------------------------------------------------------------------------------------|
| •        | Various customized prototypes in testing and development with commercial partners.                      |

----

----

----

| Evaluation of Disclosure Controls and Procedures |
|--------------------------------------------------|

----

----

----

| Exhibits: | Description                                                                                                                                                                          |           |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| 31.1      | Certification of Principal Executive Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                         | Filed herewith |
| 31.1      | Certification of Principal Financial Officer filed pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                                         | Filed herewith |
| 32.1      | Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Filed herewith |
| 10.1      | April 5, 2019 Debt settlement agreement between Rafina Innovations Inc. and Care Providers Co. Inc.                                                                                  | Filed herewith |
| 101.CAL   | XBRL Taxonomy Extension Calculation Linkbase                                                                                                                                         | *              |
| 101.DEF   | XBRL Taxonomy Extension Definition Linkbase                                                                                                                                          | *              |
| 101.INS   | XBRL Instance Document                                                                                                                                                               | *              |
| 101.LAB   | XBRL Taxonomy Extension Label Linkbase                                                                                                                                               | *              |
| 101.PRE   | XBRL Taxonomy Extension Presentation Linkbase                                                                                                                                        | *              |
| 101.SCH   | XBRL Taxonomy Extension Schema                                                                                                                                                       | *              |
|   |         | Rafina Innovations Inc. |
|--------|--------------|-------------------------|
|   |         |                    |   |
| Date:  | May 20, 2019 | By:                     | /s/ Constantinos Zertalis |
|   |         | Name:                   | Constantinos Zertalis |
|   |         | Title:                  | Chief Executive Officer and President (Principal Executive Officer) |
|   |         |                    |   |
| Date:  | May 20, 2019 | By:                     | /s/ Paraskevi Pylarinou |
|   |         | Name:                   | Paraskevi Pylarinou |
|   |         | Title:                  | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |